Corona research: Consortium of Berlin research and industry seeks active ingredients
Protein crystals are analysed in the MX laboratory at BESSY II with hard X-rays. © C. Feiler/HZB
At BESSY II, Prof. Rolf Hilgenfeld (Uni Lübeck) was able to analyse an important protein of the SARS-CoV2 virus, the viral main protease which enables the virus to multiply. © H.Tabermann/HZB
The Berlin biotech company Molox GmbH and a team at the Helmholtz-Zentrum Berlin (HZB) have initiated a consortium of regional research groups and BASF. Together, they want to identify a starting point for the development of a potential active substance against the new coronavirus. Targets of potential inhibitors will be SARS-CoV2 proteins that promote the spread or infectivity of the viruses. Scientists from Freie Universität Berlin are also involved in the research work.
"Berlin combines important large-scale infrastructure with an excellent network of academic and industrial structural biologists and biochemists. The distances here are short, but resources and expertise must be strategically coordinated to be successful," says Dr. Holger von Moeller, the owner of the biotech company Molox.
Access to synchrotron radiation is essential for the success of the project. This particularly intense radiation is provided by the Berlin Electron Storage Ring for Synchrotron Radiation (BESSY II), which is operated by the HZB.
Several research groups at Freie Universität Berlin led by Prof. Markus Wahl, Prof. Christian Freund, Dr. Ursula Neu, and Prof. Sutapa Chakrabarti are working with Molox to produce the proteins and then crystallize them.
"The HZB is making all existing infrastructures available to the joint project," explains Dr. Manfred Weiss, head of the Research Group Macromolecular Crystallography (MX) at HZB.
BASF is the first project partner from the chemical industry to provide funds to start the investigations. Protein crystals will be saturated with potential inhibitors and subsequently analysed on the MX beamlines of BESSY II. In this way it can be discovered which compounds are particularly good at inhibiting the function of the protein - these should then be the starting points for the development of active substances.
The consortium is currently negotiating with other partners in order to acquire them and their substance libraries. "We are looking forward to this joint project and hope that we will be able to identify new potential active substances against SARS-CoV-2 very quickly", says Dr. Christian Feiler, project leader at HZB.
- Research up close! The Long Night of Science at HZBOn 28 June, it's that time again: the Long Night of Science will take place from 5 pm to midnight in Berlin and also in Adlershof! Come around and take a look behind the scenes of our exciting research.
- MAX IV and BESSY II initiate new collaboration to advance materials scienceSwedish national synchrotron laboratory MAX IV and Helmholtz-Zentrum Berlin (HZB) with BESSY II light source jointly announce the signing of a 5-year Cooperation Agreement. The new agreement establishes a framework to strengthen cooperation for operational and technological development in the highlighted fields of accelerator research and development, beamlines and optics, endstations and sample environments as well as digitalisation and data science.
- Perovskites: Hybrid materials as highly sensitive X-ray detectorsNew bismuth-based organic-inorganic hybrid materials show exceptional sensitivity and long-term stability as X-ray detectors, significantly more sensitive than commercial X-ray detectors. In addition, these materials can be produced without solvents by ball milling, a mechanochemical synthesis process that is environmentally friendly and scalable. More sensitive detectors would allow for a reduction in the radiation exposure during X-ray examinations.